Entrada Therapeutics Inc TRDA
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-10-29 |
| Shares Out. | 38,820,000 |
| Website | entradatx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 152 |
| Revenue | $875,000 |
| Gross Profit | $875,000 |
| Net Income | -$39.7M |
| Free Cash Flow | -$131.8M |
| Total Assets | $335.5M |
| Total Liabilities | $64.7M |
| Equity | $270.9M |
About Entrada Therapeutics Inc
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Entrada Therapeutics Inc is a publicly traded company under the ticker symbol TRDA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)